# Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia

> **NCT00543608** · PHASE2 · TERMINATED · sponsor: **Arpida AG** · enrollment: 135 (estimated)

## Conditions studied

- Hospital-Acquired Pneumonia
- Ventilator-Associated Pneumonia
- Health-Care-Associated Pneumonia

## Interventions

- **DRUG:** iclaprim
- **DRUG:** vancomycin

## Key facts

- **NCT ID:** NCT00543608
- **Lead sponsor:** Arpida AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2009-04
- **Final completion:** 2009-05
- **Target enrollment:** 135 (ESTIMATED)
- **Why stopped:** Trial terminated due to financial resource limitations
- **Last updated:** 2009-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543608, "Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00543608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*